NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced today that it has been accepted to the BioFab Startup Lab, part of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program.
The federally-supported program, launched through a grant from the U.S. Economic Development Administration, helps early-stage biotechnology companies accelerate the translation of regenerative innovations into scalable and commercially viable manufacturing.
Recent legislation and federal initiatives, including a White House Bioeconomy Executive Orderi, have identified biomanufacturing as a strategic national capability for the U.S. and a new pillar of advanced manufacturingii.
Dr. Lior Shaltiel, CEO of NurExone, noted: "Biofabrication is becoming the industrial foundation of next-generation medicine. Federal support for programs like this reflects how U.S. priorities are expanding beyond semiconductors and clean energy toward biomanufacturing. The ARMI ecosystem and infrastructure have the potential to yield longer-term commercial benefits for the Company in GMP-grade U.S. exosome production and to accelerate the time to market for our products."
NurExone’s U.S. subsidiary, Exo-Top Inc., is advancing plans for the establishment of a GMP-compliant facility dedicated to naive exosome production. The Company believes participation in ARMI’s program will enhance its value proposition to strategic partners and shareholders.
Biofabrication is the process of using living cells and biological materials to manufacture tissues and therapeutic products. It bridges the gap between scientific discovery and industrial production, creating the foundation for a new generation of regenerative medicine technologies.
About ARMI | BioFabUSA
The Advanced Regenerative Manufacturing Institute (ARMI) is a non-profit consortium bringing together industry, academia, and government to enable large-scale manufacturing of engineered tissues and regenerative medicine products. Its six-month BioFab Startup Lab program provides early-stage companies with access to facilities, mentorship, and biomanufacturing resources that bridge the gap between discovery and market.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
